Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) is a key component of the GABAA receptor, the primary mediator of rapid inhibitory neurotransmission in the central nervous system (UniProt: P14867). This subunit typically assembles with beta and gamma subunits to form a pentameric chloride channel, with the alpha-1/beta-2/gamma-2 configuration being the most prevalent in the brain. The benzodiazepine binding site is a distinct allosteric pocket located at the interface of the alpha-1 and gamma-2 subunits. Binding of positive allosteric modulators, such as benzodiazepines and Z-drugs, increases the frequency of channel opening in response to GABA, leading to enhanced chloride influx and neuronal hyperpolarization (StatPearls: NBK513311).
Pharmacologically, the alpha-1 subunit is specifically associated with the sedative, hypnotic, and anticonvulsant effects of benzodiazepine-site ligands, whereas other alpha subunits (alpha-2, alpha-3, alpha-5) mediate anxiolytic and muscle-relaxant effects. Consequently, alpha-1 selective agents like zolpidem are widely used for the treatment of insomnia. Beyond its role as a drug target, mutations in the GABRA1 gene are linked to various idiopathic generalized epilepsies, highlighting its fundamental role in maintaining the brain's excitatory-inhibitory balance (NCBI Gene: 2554). Therapeutic challenges include the risk of sedation, motor impairment, and the potential for development of tolerance and dependence with chronic use.
Positive allosteric modulation of the GABA-induced chloride current at the alpha-1/gamma-2 subunit interface
8 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1).